Protagonist Therapeutics, Inc. Gains 45.89%
Mon, Mar 10, 2025 at 08:11 PM
Protagonist Therapeutics, Inc. (PTGX:NASDAQ) rocketted at $55.95, a gain of 45.9%. On Mon, Mar 10, 2025, PTGX:NASDAQ hit a New 2-Week High of $55.95. The stock appeared on our News Catalysts scanner on Mon, Mar 10, 2025 at 09:49 AM in the 'BIOTECH' category. From Mon, Feb 24, 2025, the stock recorded 70.00% Up Days and 54.55% Green Days
About Protagonist Therapeutics, Inc. (PTGX:NASDAQ)
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
Top 10 Gainers:
- LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 176.92%
- Heidmar Maritime Holdings Corp. (HMR:NASDAQ), 69.54%
- Redfin Corporation (RDFN:NASDAQ), 67.87%
- Checkpoint Therapeutics, Inc. (CKPT:NASDAQ), 61.13%
- Sharps Technology Inc. (STSS:NASDAQ), 48.3%
- Protagonist Therapeutics, Inc. (PTGX:NASDAQ), 45.89%
- Bally's Corporation (BALY:NYSE), 42.74%
- Mineralys Therapeutics Inc. (MLYS:NASDAQ), 42.21%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 41.16%
- Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ), 39.5%